Iovance Biotherapeutics Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
975
- Stock Symbol
-
IOVA
- Investments
-
1
- Share Price
-
$7.63
- (As of Thursday Closing)
Iovance Biotherapeutics General Information
Description
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Contact Information
Website
www.iovance.comCorporate Office
- 825 Industrial Road
- Suite 100
- San Carlos, CA 94070
- United States
Corporate Office
- 825 Industrial Road
- Suite 100
- San Carlos, CA 94070
- United States
Iovance Biotherapeutics Stock Performance
As of 12-Nov-2026, Iovance Biotherapeutics’s stock price is $7.63. Its current market cap is $3.53B with 463M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $7.63 | $8.09 | $2.08 - $15.37 | $3.53B | 463M | 16.2M | -$0.52 |
Iovance Biotherapeutics Financials Summary
As of 30-Sep-2026, Iovance Biotherapeutics has a trailing 12-month revenue of $379M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 6,713,039 | 835,414 | 1,936,833 | 1,798,723 |
| Revenue | 378,983 | 263,502 | 164,070 | 1,189 |
| EBITDA | (186,500) | (356,032) | (347,207) | (427,432) |
| Net Income | (220,535) | (390,978) | (372,177) | (444,037) |
| Total Assets | 991,214 | 913,170 | 910,426 | 780,351 |
| Total Debt | 45,210 | 49,444 | 58,261 | 75,862 |
Iovance Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Iovance Biotherapeutics Comparisons
Industry
Financing
Details
Iovance Biotherapeutics Competitors (46)
One of Iovance Biotherapeutics’s 46 competitors is Replimune, a Formerly VC-backed company based in Woburn, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Replimune | Formerly VC-backed | Woburn, MA | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom |
Iovance Biotherapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Iovance Biotherapeutics Patents
Iovance Biotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026183237-A1 | Treatment of hypermutated solid tumor cancers with tumor infiltrating lymphocyte therapies | Pending | 26-Feb-2025 | ||
| WO-2026072794-A2 | Expansion processes for til product enriched with neoantigen- reactive t cells (narts) | Pending | 26-Sep-2024 | ||
| WO-2026072794-A3 | Expansion processes for til product enriched with neoantigen- reactive t cells (narts) | Pending | 26-Sep-2024 | ||
| WO-2026050217-A2 | Engineered artificial antigen presenting cells and lipid nanoparticles for tumor infiltrating lymphocyte expansion | Pending | 27-Aug-2024 | ||
| WO-2026050217-A3 | Engineered artificial antigen presenting cells and lipid nanoparticles for tumor infiltrating lymphocyte expansion | Pending | 27-Aug-2024 | C12N5/0635 |
Iovance Biotherapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Iovance Biotherapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Iovance Biotherapeutics Acquisitions (1)
Iovance Biotherapeutics’s most recent deal was a Merger/Acquisition with Proleukin for . The deal was made on 18-May-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Proleukin | 18-May-2023 | Merger/Acquisition | Pharmaceuticals |
Iovance Biotherapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
40.89 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Iovance Biotherapeutics FAQs
-
When was Iovance Biotherapeutics founded?
Iovance Biotherapeutics was founded in 2007.
-
Where is Iovance Biotherapeutics headquartered?
Iovance Biotherapeutics is headquartered in San Carlos, CA.
-
What is the size of Iovance Biotherapeutics?
Iovance Biotherapeutics has 975 total employees.
-
What industry is Iovance Biotherapeutics in?
Iovance Biotherapeutics’s primary industry is Drug Discovery.
-
Is Iovance Biotherapeutics a private or public company?
Iovance Biotherapeutics is a Public company.
-
What is Iovance Biotherapeutics’s stock symbol?
The ticker symbol for Iovance Biotherapeutics is IOVA.
-
What is the current stock price of Iovance Biotherapeutics?
As of 12-Nov-2026 the stock price of Iovance Biotherapeutics is $7.63.
-
What is the current market cap of Iovance Biotherapeutics?
The current market capitalization of Iovance Biotherapeutics is $3.53B.
-
What is Iovance Biotherapeutics’s current revenue?
The trailing twelve month revenue for Iovance Biotherapeutics is $379M.
-
Who are Iovance Biotherapeutics’s competitors?
Replimune, Sorrento Therapeutics, Adaptimmune Therapeutics, Agenus, and Immunocore Holdings are some of the 46 competitors of Iovance Biotherapeutics.
-
What is Iovance Biotherapeutics’s annual earnings per share (EPS)?
Iovance Biotherapeutics’s EPS for 12 months was -$0.52.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
